Dyskinesia
Levodopa-induced dyskinesias — mechanisms, prevention and treatment (amantadine, DBS, etc.).
State of the art
No update yet for Dyskinesia. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Levodopa increases substantia nigra iron: implications for Parkinson's disease
Prior imaging studies have found higher nigral iron in patients with levodopa-induced dyskinesia; if levodopa drives iron accumulation, this could help explain why long-term levodopa use correlates with increased dyskinesia risk. -
Patient-Calibrated Dynamical Modeling and Embedded Trend-Zone Predictive Control for Closed-Loop Deep Brain Stimulation in Parkinson's Disease
One established benefit of reducing unnecessary stimulation through closed-loop control is lower risk of levodopa-induced dyskinesia, which is partly driven by over-stimulation. The trend-zone predictive framework described here is explicitly designed to avoid delivering excess stimulation when beta oscillations are already within an acceptable range — a design goal with direct implications for dyskinesia management in DBS patients. -
Phase 3 trial of solengepras for Parkinson’s disease now fully enrolled
Because solengepras acts on GPR6 rather than dopamine directly, it is designed to provide levodopa-like motor benefits while potentially avoiding dyskinesia — one of the key hypotheses the Phase 3 ARISE trial is now positioned to test. -
Vyalev eases motor, nonmotor symptoms in advanced Parkinson’s
In the ROSSINI real-world study, daily dyskinesia time fell by an average of 1.8 hours (53%) after six months on Vyalev, consistent with the smoother levodopa delivery reducing peak-dose involuntary movements outside of controlled trial conditions.